Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after the company revealed it had reached a ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...

Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer. Shares ...

The UK FTSE 100 index increased by 0.3%, driven by significant gains in GSK following a settlement in the U.S. The market ...

The FTSE 100 index traded up 25.77 points, 0.3%, at 8,269.51. The FTSE 250 slipped 12.69 points, 0.1%, at 20,809.69, and the AIM All-Share down just 0.19 of a point at 736.47.

Among single stocks, GSK jumped about 6% after the British drugmaker agreed to pay up to $2.2 billion to settle U.S. lawsuits ...

European stocks rose on Thursday as investors awaited key US inflation data, with the healthcare sector leading gains after ...